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Abstract
The CSN complex plays a key role in various cellular pathways: through a metalloprotease
activity of its Csn5 deneddylating enzyme, it regulates the activity of Cullin-RING ligases
(CRLs). Indeed, Csn5 has been found amplified in many tumors, but, due to its pleiotropic
effects, it is difficult to dissect its function and the involvement in cancer progression.
Moreover, while growing evidences point to the neddylation function as a good target for
drug development; specific inhibitors have not yet been developed for the CSN. Here, we
propose the yeast Saccharomyces cerevisiae as a model system to screen libraries of small
molecules as inhibitors of cullins deneddylation, taking advantage of the unique feature of
this organism to survive without a functional CSN5 gene and to accumulate a fully
neddylated cullin substrate. By combining molecular modeling and simple genetic tools, we
were able to identify two small molecular fragments as selective inhibitors of Csn5
deneddylation function.
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Introduction
The COP9 signalosome (CSN) is evolutionary conserved among
all eukaryotes, multi-subunit complex with a canonical compos-
ition of eight subunits (Csn1–8) found in all multicellular
organisms. The CSN regulates the activity of the largest family
of ubiquitin E3 ligases, called CRLs (Cullin-RING ubiquitin
ligases). Regulation of CRLs by the CSN involves the catalytic
activity of NEDD8 hydrolysis from the cullin scaffold subunit of
CRLs through a metalloprotease MPN+/JAMM motif within the
catalytic subunit, Csn5.
Through a complicated regulation sequence of neddylation and
deneddylation, CRLs commit to ubiquitinate their substrates, thus
controlling various cellular functions, including cell cycle
progression, DNA repair and cell survival.
The yeast Saccharomyces cerevisiae CSN1,2 includes only six
subunits: a most conserved catalytic subunit Csn5/Rri1 and five
divergent orthologues of canonical subunits3. Yet, the yeast CSN
harbors a canonical cullin-deneddylation activity and is able to
deneddylate mammalian cullins2. Vice versa, mammalian CSN is
able to deneddylate yeast cullins4,5. However, the knockdown of
the yeast CSN subunits neither affect viability nor the G1-S
transition promoted by the SCF, and it has a modest effect on the
turnover of SCF substrates6–8.
The key role of CSN in regulating cullin-RING ligases places
it as a central mediator of cellular functions during cancer
progression. In particular, the overexpression of CSN5 gene has
been found in many tumors, including breast cancers9,10, and
growing evidences point to a fundamental role of Csn5 as a key
driver of epithelial transformation11. Csn5 could exert its
positive function in cancer progression in different ways: first,
as part of the CSN, Csn5 is an important activator of MYC
activity12; second, in a small complex or a free form, Csn5
induces the cytoplasmic export of p27 (a tumor suppressor gene)
that is causing its ubiquitination and proteasomal degradation13–
15; third, in monomeric form, Csn5 binds and modulates
signaling proteins and transcription factors, such as hypoxia-
inducible factor-1a16. This landscape makes difficult to dissect/
identify Csn5 role in specific tumors due to its pleiotropic
function.
In the era of pharmacogenomic and personalized medicine, the
targeting of specific proteins with designed molecules became
possible. Yet, up-to-date, no specific inhibitors were selected for
Csn5, even if the CSN pathway has gained increasing attention as
a target for anticancer molecules17,18. Indeed, the Csn5 study is
challenging due to mammalian embryonic lethality of the CSN5
deletion and the instability of the protein if overespressed19.
Recently, the deneddylating activity of the CSN has been
described as a novel target of doxycycline20.
Here, we propose the yeast Saccharomyces cerevisiae as a
model system to select small molecules to target the deneddylat-
ing function of Csn5.
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Methods
Yeast strains
Saccharomyces cerevisiae strains W303 (MATa leu2–3,112, trp1–
1, can1–100, ura3–1, ade2–1, his3–11,15), Dcsn5 (MATa leu2–
3,112, trp1–1, can1–100, ura3–1, ade2–1, his3–11,15,
csn5D::KanMX), Drub1 (MATa leu2–3,112 trp1–1, can1–100,
ura3–1, ade2–1, his3–11,15, rub1D::KanMX) and rpn11-m1
(MATa leu2–3,112, trp1–1, can1–100, ura3–1, ade2–1, his3–
11,15, rpn11-m1) were used in this work. YPD (1% bacto
peptone, 1% yeast extract and 2% glucose) was used as yeast
culture-rich medium.
Cells treatments
Cells grown in rich media were diluted to 1 107 cells/ml and
200ml aliquots were placed in 96-wells microplate. Each aliquot
was treated with different concentrations of the indicated
compounds and then incubated shaking at 28 C. After 20 h
OD600 for each well was measured and plotted.
Western blot
Ten milliliter of cells grown to 1 107 cell/ml were harvested by
centrifugation, re-suspended in 1 ml of YPD containing 2 mM of
the indicated compounds or 2% dimethyl sulfoxide (DMSO), and
then incubated shaking for 2 h at 28 C. Extracts were prepared
from this cells following trichloroacedic acid (TCA) protein
precipitation.
Proteins were resolved on 10% Tris–glycine PAGE,34 trans-
ferred to PVDF membranes and immunoblotted using the
a-CDC53 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) or a-ubiquitin (Sigma-Aldrich, St. Louis, MO). The second-
ary antibodies were anti-Goat (Santa Cruz Biotechnology and
anti-Rabbit (Santa Cruz Biotechnology). The proteins were
visualized utilizing the Bio-Rad’s ChemiDoc XRS + system,
according to manufacturer’s instructions.
RNA extraction
RNA was extracted from cell cultures at OD600¼ 1 (strains were
grown in YPD medium at 28 C). Cells were suspended in 1 mL
of AE buffer (50 mM sodium acetate pH 5, 10 mM EDTA)
(AppliChem GmbH, Darmstadt, Germany), centrifuged and
suspended in 0.4 mL of AE buffer plus 1% (w/v) SDS
(AppliChem GmbH). Cells were lysed with phenol:chloroform
(5: 1, pH 4.7, Sigma-Aldrich), heated at 65 C for 10 min,
transferred at 80 C for 10 min and the aqueous phase was
separated by centrifugation. After a second extraction with
phenol:chloroform (24: 1, pH 5.2, Sigma-Aldrich), RNA was
precipitated with ethanol, dried and suspended in sterile water.
RNA quantity and purity were assessed with a Nanodrop ND-
1000 spectrophotometer (Thermo Scientific, Waltham, MA) at
260 nm and at 260/230, 260/280 nm ratios, respectively. RNA
integrity was assessed by electrophoresis on ethidium bromide
stained 1% agarose-formaldehyde gels.
RT real-time PCR
1 mg of total RNA extracted from cell cultures, 1 mg RNA was
reverse transcribed using 200 ng of 16mers oligo dT (Life
Technologies, Carlsbad, CA) with SuperScript III First-Strand
Synthesis System for RT-PCR (Life Technologies), according to
the manufacturer’s instructions. cDNA served as template for
subsequent real-time PCR reactions that were set up in duplicate
for each sample using the SensiMix SYBR Mix (Bioline, London,
UK) and an Applied Biosystems Prism 7300 Sequence Detector.
The reaction mixtures were kept at 95 C for 10 min, followed by
40 cycles at 95 C for 15 s and 60 C for 1 min. The threshold
cycle (Ct) was calculated using the Sequence Detector Systems
version 1.2.2 (Life Technologies) by determining the cycle
number at which the change in the fluorescence of the reporter
dye (DRn) crossed the threshold. To synchronize each experi-
ment, the baseline was set automatically by the software. Relative
quantification was carried out with the 2ddct method, using the
abundance of actin transcript as endogenous housekeeping
control. Data were statistically analyzed by Student’s t-test.
Molecular modeling directions
Molecular dynamics simulation
Crystal structure of Csn5/Jab1 enzyme (PDB code: 4F7O) was
downloaded from the Protein Data Bank (www.rcsb.org/pdb)21.
The chain A from the Csn51–257 crystal structure was used as the
starting structure, after manual replacement of Arg106 with Ala
(Csn5_R106A mutant). The system was solvated by means of the
System Builder tool of Desmond22,23 with a periodic orthorhom-
bic box of explicit TIP3P water molecules. Charge was
neutralized by adding three Cl ions. The entire system of
35041 atoms was relaxed by energy minimization with 2000
maximum iteration steps and a convergence threshold of 1.0 kcal/
mol/A˚. The minimization procedure is performed with a steepest-
descent algorithm (SD) until a gradient threshold of 25 kcal/mol/
A˚ is reached, then the LBFGS algorithm is used. The OPLS2005
force field was used. A weak harmonic restraint of 20 kcal/mol/A˚2
was applied to the zinc atom. Molecular dynamics simulation was
performed at constant T and P (i.e. NTP simulation), with the
OPLS 2005 force field and the following parameters: simulation
time¼ 40 ns, temperature¼ 300 K, pressure¼ 1.013 bar. A weak
harmonic restraint of 20 kcal/mol/A˚2 was applied to both the zinc
atom and the atoms directly involved in zinc coordination, namely
the two nitrogen atoms of His138 and His140 and the two oxygen
atom of Asp151. Other parameters were kept to their default
value. The distance between the zinc atom and Ala106 was
monitored by the simulation event analysis tool of Desmond.
Molecular docking
The receptor was prepared with the MAKE_RECEPTOR graph-
ical utility implemented in the OEDocking suite24 of OpenEye,
starting from the selected frame of previous molecular dynamics
simulation. A box volume of 5473 A˚3 with dimensions
17.33 16.33 19.33 A˚ covering the accessible surface of the
Csn5 catalytic groove was used. A constraint on the zinc atom was
also added. Molecules used in the docking procedure were
extracted from an in house library, by choosing small fragments
endowed with a molecular weight up to 300 Da. Selected
structures were further filtered with the FILTER application of
OpenEye25 for the presence of the carboxylate moiety and the
protonation state of each molecule was assigned by using the
FIXPKA application of QUACPAC of OpenEye26.
Conformational analysis of the database was carried out with
the OMEGA software of OpenEye (Santa Fe, NM)27,28, by
keeping a maximum of 500 conformations for each molecule.
Molecular docking was performed by means of the FRED
software (Santa Fe, NM) implemented in the OEDocking suite of
OpenEye29, by saving the best five poses for each molecule and
only for the first 50 best scored molecules. Other parameters were
kept to their default value.
Energy minimization
Docking-selected complexes were further relaxed in a box of
TIP3P explicit water molecules by energy minimization with
Desmond. The OPLS2005 force field was used. A weak harmonic
2 A. Cirigliano et al. J Enzyme Inhib Med Chem, Early Online: 1–6
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restraint of 20 kcal/mol/A˚2 was applied to both the zinc atom and
the atoms directly involved in zinc coordination, namely the two
nitrogen atoms of His138 and His140 and the two oxygen atom of
Asp151. Energy minimization was performed with 2000 max-
imum iteration steps and a convergence threshold of 1.0 kcal/mol/
A˚. The minimization procedure is performed with a SD until a
gradient threshold of 25 kcal/mol/A˚ is reached, then the LBFGS
algorithm is used.
pka and atom charge calculations
pka values were determined by the software Marvin Sketch of
ChemAxon (Budapest, Hungary)30. Atom charges were calculated
by the Antechamber/Mopac software implemented in Amber12
(San Francisco, CA)31.
Results and discussion
The MPN+/JAMM domain of Csn5 are conserved in evolution
across all eukaryotic phyla, including S. cerevisiae32,33. CRLs in
evolution and it is the metalloprotease domain responsible for the
cleavage of Nedd8 from Cullin1 (Cdc53 in S. cerevisiae), the
scaffold protein of CRL1 (a.k.a SCF)4,34. Taking advantage of the
crystal structure of the MPN+/JAMM motif and of the human
Csn5, namely Csn5/Jab1 (PDB code: 4F7O)21,35–36, we estab-
lished a structure-based computational strategy to discover small
molecular fragments as potential inhibitors of the enzyme
catalytic function (the computational screening workflow is
described in Supplementary Figure S1). First, analysis of the
above mentioned crystallographic structure revealed that the
molecular segment named Ins-1 obstructs the accessibility to the
Zn-coordinated active site of Csn5 by means of a salt-bridge
between Asp151 and the Ins-1 residue Arg106. Notably, Arg106
replacement with threonine, alanine or glycine, restores the
catalytic activity21. Therefore, to overcome this structural obstacle
to the design of Csn5 inhibitors, and following the procedure
already described by Echalier et al. (2013)21, we mutated Arg106
to alanine in silico in the crystallographic structure of Csn5
(Supplementary Figure S2A). The such generated Csn5_R106A
mutant was furthermore relaxed by energy minimization and
subsequently studied by means of molecular dynamics (MD)
simulations, which showed the release of the Ins-1 segment from
the Zn-coordinated active site during MD trajectories, in agree-
ment with previous findings21. The distance between the catalytic
Zn(II) ion and the Ins-1 residue Ala106, was monitored during
MD simulations, reaching the maximum values of 20.7 A˚ that
corresponds to a noticeable accessibility of the active site
(Supplementary Figure S2B). Overall, the R106A mutation in
silico of Csn5 followed by MD simulations provided a conform-
ation of the enzyme that resembles the catalytically competent
metalloprotease. The frame corresponding to the maximum
distance between Zn(II) and Arg106 was used as rigid receptor
in the subsequent structure-based virtual screening
(Supplementary Figure S2B).
To this end, an in house library of natural compounds and their
derivatives was used. It is worth mentioning that the library is
endowed with a significant chemical diversity and has been
already employed with success in previous hits and leads
discovery studies37,38. Based on limited structural data on the
Csn5 enzyme, the lack of reference inhibitors, and the presence of
a Zn(II) ion within the catalytic site, the library was filtered to
select only small molecular fragments, in accordance with the
‘‘Rule of Three’’39, which are endowed with a well-known zinc-
binding group40. The selected subset of fragments
(Supplementary Figure S3) was then virtually screened against
the MD-refined structure of the Csn5 enzyme by means of
molecular docking with FRED from OpenEye41–43. Docking
complexes were further relaxed by energy minimization.
Coupling visual inspection with the ranking according with the
Chemgauss4 score provided 11 small molecular fragments
(Supplementary Figure S4) as potential inhibitors of Csn5
enzyme, which were submitted to functional investigations.
We reasoned that we could take advantage of the versatility of
the yeast cells to screen for Csn5 inhibitors and for this purpose
we first searched for a rapid test to mimic/verify Csn5 inhibition.
In S. cerevisiae, the Dcsn5 strain is viable allowing us to test the
phenotypes caused by the CSN5 deletion in presence of a variety
of compounds (Supplementary Figure S5). Between the 10 tested
compounds, only nystatin produced a clear phenotype in the
deleted csn5 strain, compared with the wild-type yeast strain
(W303), suitable for inhibitors screening. Nystatin binds to
ergosterol, a major component of the fungal cell membrane
forming pores and causing yeast cells death; the sensitivity
phenotype of Dcsn5 is a consequence of its altered lipid
metabolism and indeed we previously demonstrated, by tran-
scriptomic and proteomic experiments, that the Csn5 protein is
involved in the modulation of genes controlling the aminoacid and
lipid metabolism in yeast34. We reasoned that if the 11 molecules
selected by molecular docking inhibit the Csn5 function, we
should see a drug sensitive phenotype of the wild-type cells in
presence of the selected molecules plus 0.2mg/ml nystatin
(Supplementary Figure S6). Indeed, all the 11 compounds
produced a range of sensitivity to nystatin in the wild-type cells
from compound 9 (the less sensitive) to compound 4 (the most
sensitive), indicating that the molecules could be effective in
interfering with the deneddylation function. To test this hypoth-
esis, we performed a western blot analysis to assess the
deneddylation activity on Cdc53, which is a major target of
Csn5, in a W303 strain treated with the 11 molecules in YPD
medium (Supplementary Figure S7). The results showed that
molecules 2 and 4 enhanced the sensitivity to nystatin (Figure 1A)
and inhibited the deneddylation activity of Csn5 at similar
concentration (Figure 1B). We refer to compound 2 and 4 as Csn5
specific inhibitors from now on.
According with molecular modeling, molecules 2 and 4 were
predicted to bind and coordinate the catalytic Zn(II) ion by the
carboxylic group. In 2, this moiety also establishes a H-bond
interaction with the side chain of Ser148 (Figure 2) that, together
with Glu76, is known to coordinate a catalytic water molecule in
the inactive form of the enzyme. Interestingly, the geometry of
coordination to the catalytic Zn(II) ion of 2 and 4 is very common
in crystallographic structures of ligand-bound metalloproteases
(just as e.g. see PDBs: 1ZZ0, 2WO8, 1OS2)45–48. The aromatic
portion of 2 was found to interact in a hydrophobic cleft bounded
by Trp136, Met117, Met78, Thr154 and Ile150. The same
hydrophobic interactions can be assessed for 4, although to a
lesser extent (Figure 2). Finally, as 10 out of 11 tested fragments
bear a carboxylic functional group, it was found to be crucial for
Zn-coordination, thus becoming a key structural feature of Csn5
inhibitors. Moreover, according with literature data, in case of
metal coordination the higher the pKa values of the carboxylic
group (i.e. the lower the acidity), the better are donor properties of
the carboxylate ion due to higher electron density on the oxygen
atoms49. Noteworthy, pKa of 2 and 4 resulted higher or equal to
that calculated for other fragments (Supplementary Information
Table S1), thus suggesting that pKa coupled with structural
features described above and reported in Figure 2 may be
exploited for optimizing Csn5 inhibitors.
The Csn5 has an ortholog, the proteasomal deubiquitinating
enzyme Rpn11. These two proteins share a similar MPN+/JAMM
domain, so, even if the molecules were specifically designed for
Csn5, we cannot exclude that in vivo the molecules could affect
the Rpn11 function. In order to verify that the deneddylating
DOI: 10.3109/14756366.2016.1160901 Yeast to select inhibitors of Csn5 3
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inhibition is a direct effect of the molecules in the Csn5 catalytic
site and it is not due to a block of Rpn11 proteasomal function, we
looked at the profile of ubiquitinated proteins in the cells treated
with the inhibitor 2; as a control we used the proteasomal
rpn11-m1 mutant, which accumulates polyubiquitinated proteins
due to the block of degradation50; the result showed that cells
treated with inhibitor no. 2 did not accumulate polyubiquitinated
proteins after 30 or 60 min of treatment, indicating that the
inhibition was specific for cullin deneddylation function
(Supplementary Figure S8).
The transcriptomic profile of Dcsn5 strain has been previ-
ously defined34. In order to assess if the catalytic inhibition of
Csn5 is able to recapitulate some of the transcriptional effects of
Csn5 deletion, we quantified by real-time RT-PCR the
expression of two genes (ERO1 and IZH2), which are typically
down-regulated in Dcsn5 strains, in the W303 strain treated with
inhibitors 2 and 4. Indeed we observed that in the presence of
these compounds, the mRNA of both genes is reduced in an
extent very similar to that observed in the isogenic Dcsn5 strain
(Figure 3). This result suggests that the transcriptional effects
observed in the deleted strain are due to the loss of Csn5
catalytic activity.
The study of Csn5 function is greatly complicated by its
multiple roles as single protein or in complex with CSN partners,
some of which do not require its catalytic function. The
availability of specific functional inhibitors is therefore essential
to identify the effects directly associated with the complex-
dependent cullin-deneddylation activity.
Figure 1A. Dose-response curve obtained
with molecules 2 and 4. W303 wild-type
strain and Dcsn5 were grown in YPD medium
and W303 treated over night with molecules
2 and 4 or with DMSO only (at the same
concentration used to dissolve the com-
pounds). Nt indicates non-treated with
nystatin. The compounds 2 and 4 enhance
sensitivity to nystatin mimicking the Dcsn5
behavior. The drastic sensitivity of Dcsn5
cells is due to the complete absence of Csn5
enzyme in these cells.
Figure 2. Binding mode of 2 (a) and 4 (b) predicted by molecular docking and energy minimization. Csn5 is shown as cartoon. Residues within 4 A˚
from the ligand are labeled and showed as thin sticks. Zn(II) ion is labeled and showed as sphere. Ligand is shown as thin sticks. Metal coordination of 2
and 4, as well as the H-bond between the carboxylate of 2 and the side chain of Ser148 are reported in dashed line.
4 A. Cirigliano et al. J Enzyme Inhib Med Chem, Early Online: 1–6
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